山东医药2017，Vol.57Issue(37)：1-4,4.DOI:10.3969/j.issn.1002-266X.2017.37.001
CYP3A4基因18B位点多态性与晚期EGFR基因突变NSCLC患者疗效及不良反应的关系
Relationships of CYP3A4 gene 18B polymorphisms with efficacy and adverse reactions in advanced NSCLC patients with EGFR gene mutation
摘要
Abstract
Objective To explore the relationships of cytochrome 3A4 (CYP3A4) gene 18B polymorphisms (CYP3A4 * 18B) on the efficacy and adverse reactions in advanced non-small-cell lung cancer (NSCLC) patients with EGFR gene mutation.Methods Forty-four patients with newly diagnosed advanced NSCLC were chosen and treated with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) gefitinib 250 mg,once a day,or erlotinib 150 mg,once a day;when the patients could not tolerate the adverse reactions,we stop the medication.PCR and the direct sequencing were carried out to determine the mutations of CYP3A4 * 18B before treatmeut,and then we compared the efficacy (objective response rate,disease control rate) and adverse reactions between mutant type and wild type patients.Results The mutation frequency of CYP3A4 * 18B gene was 36.4％ (16/44),among which wild type homozygote accounted for 63.6％ (28/44),mutant heterozygote accounted for 34.1％ (15/44),and mutant homozygote accounted for 2.3％ (1/44).There was no significant difference in efficacy of EGFR-TKI between wild type and mutant type patients (all P ＞0.05).Patients with CYP3A4 * 18B gene wild type had a higher incidence of rash than that of the mutant type (P ＜0.05).Conclusion The polymorphism of CYP3A4 gene 18B is not related to the efficacy of EGFR-TKI for advanced NSCLC patients with EGFR gene mutation,but is related to the adverse reactions of drugs.关键词
非小细胞肺癌/细胞色素3A4/表皮生长因子/基因多态性/酪氨酸激酶抑制剂/治疗结果/不良反应Key words
non-small-cell lung cancer/cytochrome 3A4/epidermal growth factor/gene polymorphism/tyrosine kinase inhibitor/therapeutic outcome/adverse reactions分类
医药卫生引用本文复制引用
程艳芳,费晶,王艳娜,王慧,孟玲利,巩平..CYP3A4基因18B位点多态性与晚期EGFR基因突变NSCLC患者疗效及不良反应的关系[J].山东医药,2017,57(37):1-4,4.基金项目
国家自然科学基金资助项目(81560381) （81560381）
吴阶平研究课题资助项目(320.6750.14269). （320.6750.14269）
